MicuRx Pharmaceuticals, Inc. Better Therapy Through Superior Medicines About MicuRx Anti-infective medicines are essential and often critical aids vital for the health care of the population at large, in particular, for the well-being of young, elderly, and immuno-compromised people. Their role in maintaining the quality of the human life only increases in time, and this established trend will continue as baby boomers age and numbers of immunocompromised patients grow. Both hospital and community patients benefit from innovative antibacterial, antifungal, and antiviral pharmaceuticals. Thus, the novel effective medicines are urgently needed to address the well-recognized and growing threat of drug-resistant microorganisms. Another important opportunity is the creation of superior selective and safer medicines with potential for improved therapies that are minimally disruptive for a patient due to dramatically reduced or eliminated side effects. These characteristics would allow for a faster patient recovery resulting in significant pharmacoeconomic and societal benefits. Building on team's past experience and achievements, including most recent success while at Vicuron Pharmaceuticals Inc., MicuRx is pursuing the discovery, development, manufacturing and commercialization of vital medicines that meet specific needs of hospital and community patients. Our innovative scientific strategy is based on a highly focused approach that harnesses the unique vision and expertise of the team to enable the expedited delivery of high quality anti-infective products. MicuRx business strategy seeks to capitalize on the global opportunities emerging through the combination of biotech pharma innovation in the USA and the enterprise-friendly infrastructure and scientific resources of China. This approach affords MicuRx with utmost efficiency in the drug discovery and development process. Importantly, the strategy also sets the stage for an expedited access of MicuRx products to the global pharmaceuticals markets. 关于 MicuRx : MicuRx 是由美国资深药物开发企 业家创投，受到实力雄厚风 险投资基金 Morningside 支持的，以研发一类小 分子新药为主的新型药 物公司。 MicuRx 创始人也是 Vicuron Pharmaceuticals, Inc. 的创始人之一。（ Vicuron 于 2005 年被辉瑞以 20 亿美元收购。） MicuRx 在美国旧金山湾区 和上海张江科学园区都 有研发基地。 Discovery and Development